The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia : Seven patients' experience at a DALI apheresis center
Copyright: © 2020 Annals of Pediatric Cardiology..
INTRODUCTION: Familial hypercholesterolemia (FH) is characterized by severe hypercholesterolemia that can result in coronary artery disease occurring at an early age. If patients are not cured with lipid-lowering drugs and diets, lipid apheresis may be an effective treatment option in these cases. Here, we evaluate the efficacy, selectivity and safety of the DALI apheresis technique.
MATERIALS AND METHODS: Seven pediatric patients (2 girls; 5 boys) with ages between 7 and 14 years (mean age: 6.5±2.1 years) with HFH were included in this study. We restrospectively evaluated clinical and laboratory findings. We used the DALI system for lipid apheresis concomitant with medical treatment and diet for hyperlipidemia.
RESULTS: The cohort's mean T.cholesterol level prior to apheresis was 700.57±136.36 mg/dl,the mean LDL-C value was 526.86±131.56 mg and the mean HDL-C level was 36.57±4.58 mg/dl.The mean cholesterol levels after apheresis were consecutively 317.57±93.70 /257.29±90.38 / 33.36±4.78 mg/dl.We noted a 51.1% reduction in LDL-C level and an 8.7% reduction in HDL-C level in our apheresis sessions.The reduction in LDL-C was statistically significant (p<0.05). During 1025 apheresis therapy, the most frequent mild and moderate adverse events were deviceaccess problems and hypotension (in all patients);severe adverse events were mainly due to cardiac problems(myocardial infarct and arrhythmia) and hypotension.
CONCLUSION: Lipid apheresis is an inevitable alternative treatment for HFH. Despite all of its application problems, DALI system is an effective therapy for decreasing atherogenic lipids from circulation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Annals of pediatric cardiology - 13(2020), 2 vom: 08. Apr., Seite 111-116 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bulut, Muhammet [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
DALI system |
|---|
| Anmerkungen: |
Date Revised 15.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4103/apc.APC_56_19 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312191693 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312191693 | ||
| 003 | DE-627 | ||
| 005 | 20231225143901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4103/apc.APC_56_19 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1040.xml |
| 035 | |a (DE-627)NLM312191693 | ||
| 035 | |a (NLM)32641881 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bulut, Muhammet |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of DALI lipid apheresis in the prognosis of homozygous familial hypercholesterolemia |b Seven patients' experience at a DALI apheresis center |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2020 Annals of Pediatric Cardiology. | ||
| 520 | |a INTRODUCTION: Familial hypercholesterolemia (FH) is characterized by severe hypercholesterolemia that can result in coronary artery disease occurring at an early age. If patients are not cured with lipid-lowering drugs and diets, lipid apheresis may be an effective treatment option in these cases. Here, we evaluate the efficacy, selectivity and safety of the DALI apheresis technique | ||
| 520 | |a MATERIALS AND METHODS: Seven pediatric patients (2 girls; 5 boys) with ages between 7 and 14 years (mean age: 6.5±2.1 years) with HFH were included in this study. We restrospectively evaluated clinical and laboratory findings. We used the DALI system for lipid apheresis concomitant with medical treatment and diet for hyperlipidemia | ||
| 520 | |a RESULTS: The cohort's mean T.cholesterol level prior to apheresis was 700.57±136.36 mg/dl,the mean LDL-C value was 526.86±131.56 mg and the mean HDL-C level was 36.57±4.58 mg/dl.The mean cholesterol levels after apheresis were consecutively 317.57±93.70 /257.29±90.38 / 33.36±4.78 mg/dl.We noted a 51.1% reduction in LDL-C level and an 8.7% reduction in HDL-C level in our apheresis sessions.The reduction in LDL-C was statistically significant (p<0.05). During 1025 apheresis therapy, the most frequent mild and moderate adverse events were deviceaccess problems and hypotension (in all patients);severe adverse events were mainly due to cardiac problems(myocardial infarct and arrhythmia) and hypotension | ||
| 520 | |a CONCLUSION: Lipid apheresis is an inevitable alternative treatment for HFH. Despite all of its application problems, DALI system is an effective therapy for decreasing atherogenic lipids from circulation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DALI system | |
| 650 | 4 | |a HDL cholesterol | |
| 650 | 4 | |a LDL apheresis | |
| 650 | 4 | |a LDL cholesterol | |
| 650 | 4 | |a familial hypercholesterolemia | |
| 700 | 1 | |a Nisli, Kemal |e verfasserin |4 aut | |
| 700 | 1 | |a Dindar, Aygün |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of pediatric cardiology |d 2008 |g 13(2020), 2 vom: 08. Apr., Seite 111-116 |w (DE-627)NLM19648636X |x 0974-2069 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:2 |g day:08 |g month:04 |g pages:111-116 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4103/apc.APC_56_19 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 2 |b 08 |c 04 |h 111-116 | ||